Table 3 Comparison of the use of specific antimicrobial classes and agents measured in defined daily doses per 1000 patient days in the pre- and post-intervention periods. P-values meeting the pre-specified Bonferroni corrected significance threshold are bolded.

TNICU

antibacterials

1409 (203)

1001 (232)

0.0001

antibacterials with antipseudomonal activity

349 (89)

195 (62)

<0.0001

antifungals

24(24)

36 (25)

0.33

penicillin

15 (21)

19 (24)

0.63

ampicillin

86 (67)

52 (39)

0.24

cloxacillin

337(127)

235(128)

0.068

piperacillin-tazobactam

72 (15)

71 (30)

0.71

cefazolin

189 (55)

138 (43)

0.028

ceftriaxone

78 (35)

67 (41)

0.29

ceftazidime

52 (40)

34 (21)

0.41

ertapenem

4 (7)

3 (7)

0.47

meropenem

11 (18)

22 (32)

0.23

imipenem

9 (10)

16 (14)

0.20

fluoroquinolones

210 (81)

43 (32)

<0.0001

TMP-SMX

76 (73)

83 (57)

0.67

azithromycin

12 (13)

21 (16)

0.20

vancomycin

203 (110)

134 (52)

0.068

aminoglycosides

4 (8)

8 (10)

0.18

MSICU

antibacterials

1547 (274)

1715 (263)

0.16

antibacterials with antipseudomonal activity

445 (136)

588 (196)

0.028

antifungals

177 (195)

202 (124)

0.14

penicillin

55 (48)

44 (68)

0.29

ampicillin

81 (58)

94 (89)

0.98

cloxacillin

166 (119)

136(66)

0.93

piperacillin-tazobactam

197 (53)

200 (34)

0.98

cefazolin

68 (29)

83 (30)

0.35

ceftriaxone

97 (27)

113 (40)

0.48

ceftazidime

28 (21)

32 (29)

0.98

ertapenem

19 (24)

15 (15)

0.77

meropenem

28 (48)

55 (51)

0.033

imipenem

49 (35)

47 (28)

0.84

fluoroquinolones

138 (49)

180 (60)

0.078

TMP-SMX

118 (93)

85 (41)

0.63

azithromycin

101 (42)

132 (53)

0.11

vancomycin

153 (38)

175 (43)

0.18

aminoglycosides

29 (34)

55 (43)

0.088